Browse PDGFRA

Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Note=The activated receptor is rapidly internalized and degraded.
Domain PF07679 Immunoglobulin I-set domain
PF07714 Protein tyrosine kinase
Function

Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001553 luteinization
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001822 kidney development
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006979 response to oxidative stress
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007548 sex differentiation
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010543 regulation of platelet activation
GO:0010544 negative regulation of platelet activation
GO:0010863 positive regulation of phospholipase C activity
GO:0010927 cellular component assembly involved in morphogenesis
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014706 striated muscle tissue development
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019216 regulation of lipid metabolic process
GO:0022602 ovulation cycle process
GO:0030168 platelet activation
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030239 myofibril assembly
GO:0030258 lipid modification
GO:0030335 positive regulation of cell migration
GO:0031032 actomyosin structure organization
GO:0031532 actin cytoskeleton reorganization
GO:0032102 negative regulation of response to external stimulus
GO:0032835 glomerulus development
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033674 positive regulation of kinase activity
GO:0034109 homotypic cell-cell adhesion
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035051 cardiocyte differentiation
GO:0035239 tube morphogenesis
GO:0035790 platelet-derived growth factor receptor-alpha signaling pathway
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0038086 VEGF-activated platelet-derived growth factor receptor signaling pathway
GO:0038091 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042692 muscle cell differentiation
GO:0042698 ovulation cycle
GO:0043010 camera-type eye development
GO:0043410 positive regulation of MAPK cascade
GO:0043550 regulation of lipid kinase activity
GO:0043551 regulation of phosphatidylinositol 3-kinase activity
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity
GO:0045137 development of primary sexual characteristics
GO:0045740 positive regulation of DNA replication
GO:0045834 positive regulation of lipid metabolic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0046777 protein autophosphorylation
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048511 rhythmic process
GO:0048514 blood vessel morphogenesis
GO:0048546 digestive tract morphogenesis
GO:0048557 embryonic digestive tract morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048566 embryonic digestive tract development
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048738 cardiac muscle tissue development
GO:0048863 stem cell differentiation
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050878 regulation of body fluid levels
GO:0050920 regulation of chemotaxis
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051146 striated muscle cell differentiation
GO:0051272 positive regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051493 regulation of cytoskeleton organization
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0055003 cardiac myofibril assembly
GO:0055006 cardiac cell development
GO:0055007 cardiac muscle cell differentiation
GO:0055013 cardiac muscle cell development
GO:0055074 calcium ion homeostasis
GO:0055123 digestive system development
GO:0060041 retina development in camera-type eye
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060326 cell chemotaxis
GO:0060537 muscle tissue development
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0061298 retina vasculature development in camera-type eye
GO:0061437 renal system vasculature development
GO:0061438 renal system vasculature morphogenesis
GO:0061439 kidney vasculature morphogenesis
GO:0061440 kidney vasculature development
GO:0061458 reproductive system development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070527 platelet aggregation
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072012 glomerulus vasculature development
GO:0072102 glomerulus morphogenesis
GO:0072103 glomerulus vasculature morphogenesis
GO:0072104 glomerular capillary formation
GO:0072210 metanephric nephron development
GO:0072224 metanephric glomerulus development
GO:0072239 metanephric glomerulus vasculature development
GO:0072275 metanephric glomerulus morphogenesis
GO:0072276 metanephric glomerulus vasculature morphogenesis
GO:0072277 metanephric glomerular capillary formation
GO:0072497 mesenchymal stem cell differentiation
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0090218 positive regulation of lipid kinase activity
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1900274 regulation of phospholipase C activity
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903725 regulation of phospholipid metabolic process
GO:1903727 positive regulation of phospholipid metabolic process
GO:1904888 cranial skeletal system development
GO:2000147 positive regulation of cell motility
GO:2000249 regulation of actin cytoskeleton reorganization
GO:2000736 regulation of stem cell differentiation
GO:2000739 regulation of mesenchymal stem cell differentiation
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005017 platelet-derived growth factor-activated receptor activity
GO:0005018 platelet-derived growth factor alpha-receptor activity
GO:0005021 vascular endothelial growth factor-activated receptor activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005161 platelet-derived growth factor receptor binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0038085 vascular endothelial growth factor binding
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0048407 platelet-derived growth factor binding
GO:0052813 phosphatidylinositol bisphosphate kinase activity
GO:0070851 growth factor receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04020 Calcium signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04540 Gap junction
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PDGFRA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PDGFRA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18337760Kidney CarcinomaImmunotherapy targetSorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor.
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PDGFRA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PDGFRA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0610.0482
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.8760.153
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4460.592
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.140.782
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5010.817
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9480.723
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4190.531
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8660.553
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.220.901
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2690.815
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9550.154
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2270.211
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PDGFRA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1110.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.111.9-0.81
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PDGFRA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PDGFRA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PDGFRA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PDGFRA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PDGFRA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PDGFRA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPDGFRA
Nameplatelet-derived growth factor receptor, alpha polypeptide
Aliases CD140a; PDGFR2; GAS9; PDGFR-2; RHEPDGFRA; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; ......
Chromosomal Location4q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PDGFRA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PDGFRA.
ID Name Drug Type Targets #Targets
DB00102BecaplerminBiotechA2M, PDGFRA, PDGFRB3
DB00619ImatinibSmall MoleculeABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB7
DB01268SunitinibSmall MoleculeCSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB8
DB05146XL820Small MoleculeKDR, KIT, PDGFRA, PDGFRB4
DB06043OlaratumabBiotechPDGFRA1
DB06589PazopanibSmall MoleculeFGF1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B310
DB06595MidostaurinSmall MoleculeFLT3, KDR, KIT, PDGFRA, PDGFRB, PRKCA6
DB08896RegorafenibSmall MoleculeABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, ......18
DB08901PonatinibSmall MoleculeABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......15
DB12742AmuvatinibSmall MoleculeFLT3, KIT, MET, PDGFRA, RAD51, RET6